Ceragenix Enter Into Agreement With BioPro

Ceragenix has entered into an exclusive distribution and supply agreement with BioPro Pharmaceutical, to commercialize EpiCeram, a prescription topical cream for treating atopic dermatitis and other dry skin conditions, in Hong Kong and Taiwan.

The agreement grants BioPro exclusivity in the territories for the distribution and marketing of EpiCeram, while Ceragenix will be responsible for the manufacturing and supply of the product. BioPro is also responsible for obtaining regulatory clearance to market EpiCeram in Hong Kong and Taiwan. Financial terms were not disclosed.

Steven Porter, chairman and chief executive officer of Ceragenix, said: “We are very pleased to expand our Asian footprint for EpiCeram by partnering with BioPro. We are very impressed with their capabilities and we look forward to working with them.”

Peter Huang, chairman and CEO of BioPro Pharmaceutical, said: “We are delighted to enter into this agreement for the distribution and supply of Ceragenix’s EpiCeram for treating atopic dermatitis and other dry skin conditions. There is an unmet medical need in that use of EpiCeram has been shown to be very effective in comparison with a number of steroidal based products while offering an improved margin of clinical safety. The introduction of EpiCeram is a terrific addition to our current line of products.”